Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996445 · ClinicalTrials.gov registry record · Phase 1
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by Xencor.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05996445: Clinical Trial Phase 1 study, sponsored by Xencor.
NCT05996445 is a Phase 1 study that was terminated before completion, run by Xencor. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05996445, a Phase 1 study, was terminated before completion, sponsored by Xencor.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to identify the recommended dose regimen that is safe and biologically effective for XmAb662.
Primary Outcome
Safety and tolerability as assessed by incidence of DLTs and all available data which will be used to determine the recommend dose(s)
Interventions
- BIOLOGICAL Keytruda® (pembrolizumab)
- BIOLOGICAL XmAb662
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2024-05-21 |
| Phase | Phase 1 |
Why NCT05996445 stopped before completion
NCT05996445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Keytruda® (pembrolizumab) is the first listed.
NCT05996445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05996445 about?
NCT05996445 is a clinical study titled "A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous administration of XmAb662 monotherapy or in combination with pembrolizumab in subjects with advanced solid tumors and to identify the recommended dose regimen that is safe and biologically effectiv...
What is the current status of trial NCT05996445?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-07-28. Estimated completion is 2024-05-21.
What interventions are being tested in trial NCT05996445?
The interventions under investigation include: Keytruda® (pembrolizumab) (BIOLOGICAL), XmAb662 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05996445?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05996445's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI